Imperial College London, and the Prescribing Observatory for Mental Health (POMH), Royal College of Psychiatrists' Centre for Quality Improvement, London, UK.
Br J Psychiatry. 2012 Sep;201(3):221-6. doi: 10.1192/bjp.bp.111.107631. Epub 2012 Jul 12.
Up to a quarter of people in the UK with a diagnosis of dementia are prescribed an antipsychotic in any year. The potential risks of such treatment are becoming clearer, but the benefits remain uncertain. Concern about the frequency and quality of such prescribing was expressed in the National Dementia Strategy for England in 2009.
To provide an estimate of the prevalence of antipsychotic use for dementia in secondary mental health services in the UK and to collect data relevant to quality improvement initiatives for such prescribing practice.
In the context of a UK quality improvement programme, relevant clinical audit data were collected for patients with dementia under the care of specialist older people's mental health services.
Fifty-four mental health National Health Service (NHS) trusts submitted data on 10 199 patients. Of those patients without comorbid psychotic illness, 1620 (16%) were prescribed an antipsychotic; the common clinical indications for such medication were agitation, psychotic symptoms, aggression and distress. Multivariable regression found younger age, care home or in-patient setting, vascular or Parkinson's disease dementia and greater severity of dementia to be all significantly associated with being prescribed antipsychotic medication. Of the 1001 (62%) patients prescribed treatment for more than 6 months, only three-quarters had a documented review of therapeutic response in the previous 6 months.
The data reveal areas of relatively good current practice, including consideration of alternatives to antipsychotic medication and clear documentation of target symptoms. They also suggest areas for improvement, such as the frequency and quality of review of long-term medication. Strategies to reduce antipsychotic use should take account of the demographic and clinical variables predicting increased likelihood of antipsychotic prescription.
在英国,每年被诊断患有痴呆症的人群中,有四分之一的人会被开处抗精神病药物。这种治疗的潜在风险越来越明显,但疗效仍不确定。2009 年的《英格兰国家痴呆症战略》表达了对这种处方的频率和质量的担忧。
估计英国二级精神卫生服务中用于痴呆症的抗精神病药物的使用流行率,并收集与这种处方实践质量改进举措相关的数据。
在英国质量改进计划的背景下,为在专科老年人心理健康服务下接受治疗的痴呆症患者收集了相关临床审计数据。
54 家心理健康国民保健服务(NHS)信托机构提交了 10199 名患者的数据。在没有合并精神病的患者中,有 1620 名(16%)被开处了抗精神病药物;这种药物的常见临床指征是激越、精神病症状、攻击和痛苦。多变量回归发现,年龄较小、在护理院或住院环境、血管性或帕金森病痴呆以及痴呆严重程度较高,均与开处抗精神病药物显著相关。在 1001 名(62%)接受超过 6 个月治疗的患者中,只有 3/4的患者在过去 6 个月中有记录对治疗反应的审查。
数据揭示了当前相对较好的实践领域,包括考虑替代抗精神病药物和明确记录目标症状。但也存在改进的空间,如长期药物治疗的审查频率和质量。减少抗精神病药物使用的策略应考虑到预测增加抗精神病药物处方可能性的人口统计学和临床变量。